News

Net profit of Jenburkt Pharmaceuticals declined 24.39% to Rs 5.89 crore in the quarter ended June 2026 as against Rs 7.79 crore during the previous quarter ended June 2025. Sales declined 0.06% to Rs 35.51 crore in the quarter ended June 2026 as against Rs 35.53 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales35.5135.53 0 OPM %16.9825.19 - PBDT7.4110.90 -32 PBT6.7710.18 -33 NP5.897.79 -24 Powered by Capital Market - Live News

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 August 2026.

Jenburkt Pharmaceuticals announced that the 41th Annual General Meeting(AGM) of the company will be held on 4 September 2026.

Jenburkt Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 5 May 2026, inter alia, have recommended the final dividend of Rs 20.7 per equity Share (i.e. 207%) , subject to the approval of the shareholders.

Net profit of Jenburkt Pharmaceuticals rose 27.05% to Rs 10.85 crore in the quarter ended March 2026 as against Rs 8.54 crore during the previous quarter ended March 2025. Sales rose 8.72% to Rs 44.63 crore in the quarter ended March 2026 as against Rs 41.05 crore during the previous quarter ended March 2025.For the full year,net profit rose 8.36% to Rs 34.74 crore in the year ended March 2026 as against Rs 32.06 crore during the previous year ended March 2025. Sales rose 11.24% to Rs 168.74 crore in the year ended March 2026 as against Rs 151.69 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales44.6341.05 9 168.74151.69 11 OPM %31.9326.46 -25.9226.63 - PBDT18.4712.63 46 53.5846.66 15 PBT17.6611.84 49 50.4743.93 15 NP10.858.54 27 34.7432.06 8 Powered by Capital Market - Live News